Navigation Links
Keryx Biopharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
Date:11/24/2009

NEW YORK, Nov. 24 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, is scheduled to present at the Piper Jaffray 21st Annual Health Care Conference being held in New York City.

Mr. Bentsur's presentation will be webcast live on Wednesday, December 2nd at 10:30AM ET and will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, a key signaling cascade that has been shown to induce cell growth and cell transformation. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types, with a Phase 3 in multiple myeloma, under Special Protocol Assessment (SPA), pending commencement by year-end. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosph
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015 Research and ... of the "An Introduction to Medical Device ... 2-3, 2015)" conference to their offering. ... introduction to the regulations and requirements that apply ... highly interactive, using real life examples and state-of- ...
(Date:9/2/2015)... , Sept. 2, 2015 Research and ... the "New EU Pharmacovigilance Legislation (London, UK - ... The 15 new EU modules concerning Pharmacovigilance ... Pharmacovigilance is conducted in Europe . ... these modules and their requirements, examine how they overlap ...
(Date:9/2/2015)... Sept. 2, 2015  ArmaGen, Inc., a privately ... to treat severe neurological disorders, announced today that ... multi-center Phase 1/2a clinical trial of AGT-181 in ... AGT-181 is an investigational enzyme ... I. The most severe form of MPS I, ...
Breaking Medicine Technology:An Introduction to Medical Device Software: Regulations and Requirements Course - London, UK - November 2-3, 2015 2ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 2ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 3ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 4
... 18 New data evaluating the impact of screening ... prostate cancer screening. The Prostate Conditions Education Council ... a leader in prostate cancer screening, announced today that ... from two studies, including the preliminary data from the ...
... Platform Designed for Radial Strength, FlexibilityHOUSTON, March 18 ... in the development and marketing of minimally invasive ... Drug Administration (FDA) has approved an investigational device ... its SUPERA stent, a novel stent platform designed ...
Cached Medicine Technology:Leader in Prostate Health Urges Prostate Cancer Screening in Face of Contradicting Data 2Leader in Prostate Health Urges Prostate Cancer Screening in Face of Contradicting Data 3U.S. Food and Drug Administration Clears Way for Multi-Center Clinical Trial of IDEV Technologies' SUPERA Peripheral Stent 2
(Date:9/3/2015)... ... September 03, 2015 , ... The ... Clinicians Report of Provo, Utah. The Clinicians Report is a leading information source ... dentists located throughout the U.S. Whiter Image's In-Office whitening kits were favorably validated ...
(Date:9/3/2015)... ... September 03, 2015 , ... At Renew Man™, we ... with the traditional health care model, where the primary care physician dictates and the ... want to become educated about their health issues and empowered to choose their own ...
(Date:9/3/2015)... ... ... When looking at the types of people who have a hard time gaining weight ... a weak appetite or those that have a fast metabolism. In order to help those ... gives three tips for slowing down metabolism. , The first thing to do is to ...
(Date:9/3/2015)... Rosa, CA (PRWEB) , ... September 03, 2015 , ... About 220,800 new cases of ... One in seven men will be diagnosed with prostate cancer during their lifetime. While only ... to six of every 10 men by age 65, according to the American Cancer ...
(Date:9/3/2015)... , ... September 03, 2015 , ... Local filmmakers and ... Hannah & Michael Habernig from Path 11 Productions have had great success in launching ... podcast has featured Hay House authors, Teal Swan who is the well known Spiritual ...
Breaking Medicine News(10 mins):Health News:Whiter Image Products Get Positive Rating From The Clinicians Report 2Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 2Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 3Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 2Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 3Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 2Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 3Health News:Path 11 Podcast Now Features over 20 Metaphysical Discussions on iTunes and Growing 2Health News:Path 11 Podcast Now Features over 20 Metaphysical Discussions on iTunes and Growing 3
... ... ... , ... , , , ...
... ... this weekend, taking the Olympic Gold Medal at the 2010 Vancouver Winter Olympics, bringing SpiderTech, ... ... World Champion USA1 4-man Bobsled team, steamed to new heights this weekend, taking the Olympic ...
... ... Marathon des Sables, a 250km (155 miles) race across the Sahara desert this April 2010. Gary ... , ... The Marathon des Sables will cover 250km/155 miles (in sections approximate to 25, 34, 38, 82, ...
... DC, USA Today, during the 39th Annual ... convening at the Walter E. Washington Convention Center ... Ohio State University, will present a poster of ... Modulation Facilitating Oral-Squamous-Cell Carcinoma Progression." Tong and a ...
... ... ... ... ...
... link between breathing in dirty air and heart problems ... to the air pollution particles caused by traffic has ... researchers say. , In the new report, researchers analyzed ... who were assessed every four years between 1995 and ...
Cached Medicine News:Health News:Christiana Care Health System Wins National Award for Innovation 2Health News:Christiana Care Health System Wins National Award for Innovation 3Health News:SpiderTech Rides the Night Train to Olympic Gold 2Health News:SpiderTech Rides the Night Train to Olympic Gold 3Health News:SpiderTech Rides the Night Train to Olympic Gold 4Health News:Mt. Everest Summiter Gary Guller (With One Arm) To Race Across Sahara in "The World's Toughest Stage Race" 2Health News:Mt. Everest Summiter Gary Guller (With One Arm) To Race Across Sahara in "The World's Toughest Stage Race" 3Health News:MedCAREERS GROUP, Inc. Reaches Agreement in Principle to Acquire StaffMD 2Health News:MedCAREERS GROUP, Inc. Reaches Agreement in Principle to Acquire StaffMD 3Health News:MedCAREERS GROUP, Inc. Reaches Agreement in Principle to Acquire StaffMD 4Health News:MedCAREERS GROUP, Inc. Reaches Agreement in Principle to Acquire StaffMD 5Health News:Years of Exposure to Traffic Pollution Raises Blood Pressure 2
Intermittent catheter...
Intermittent catheter...
Intermittent catheter...
Disease diagnosis and treatment reference sourced from Griffith's 5-Minute Clinical Consult. Save time diagnosing and treating more than 1,200 diseases and conditions....
Medicine Products: